{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:07:34Z","timestamp":1791857254036,"version":"4.3.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Established in July 2012, Enroll-HD is both an integrated clinical research platform and a worldwide observational study designed to meet the clinical research requirements necessary to develop therapeutics for Huntington's disease (HD). The platform offers participants a low-burden entry into HD research, providing a large, well-characterized, research-engaged cohort with associated clinical data and biosamples that facilitates recruitment into interventional trials and other research studies. Additional studies that use Enroll-HD data and\/or biosamples are built into the platform to further research on biomarkers and outcome measures. Enroll-HD is now operating worldwide in 21 countries at 159 clinical sites across four continents\u2014Europe, North America, Latin America, and Australasia\u2014and has recruited almost 25,000 participants, generating a large, rich clinical database with associated biosamples to expedite HD research; any researcher at a verifiable research organization can access the clinical datasets and biosamples from Enroll-HD and nested studies. Important operational features of Enroll-HD include a strong emphasis on standardization, data quality, and protecting participant identity, a single worldwide study protocol, a flexible EDC system capable of integrating multiple studies, a comprehensive monitoring infrastructure, an online portal to train and certify site personnel, and standardized study documents including informed consent forms and contractual agreements.<\/jats:p>","DOI":"10.3389\/fneur.2021.667420","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T06:04:24Z","timestamp":1629266664000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":76,"title":["Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington's Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Swati","family":"Sathe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Levey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Neacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robi","family":"Blumenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alzbeta","family":"M\u00fchlb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Rosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Bernhard","family":"Landwehrmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mdc3.12388","article-title":"Data analytics from Enroll-HD, a Global Clinical Research Platform for Huntington's Disease","volume":"4","author":"Landwehrmeyer","year":"2016","journal-title":"Mov Disord Clin Pract."},{"key":"B2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington's disease: a clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J Rare Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","article-title":"The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis","volume":"27","author":"Pringsheim","year":"2012","journal-title":"Mov Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","article-title":"The prevalence of Huntington's disease","volume":"46","author":"Rawlins","year":"2016","journal-title":"Neuroepidemiology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington's disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur J Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fnagi.2014.00078","article-title":"Clinical and biomarker changes in premanifest huntington disease show trial feasibility: a decade of the PREDICT-HD study","volume":"6","author":"Paulsen","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.parkreldis.2014.12.013","article-title":"Update on Huntington's disease: advances in care and emerging therapeutic options","volume":"21","author":"Zielonka","year":"2015","journal-title":"Parkinsonism Relat Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/mdc3.12808","article-title":"Movement disorder society task force viewpoint: Huntington's disease diagnostic categories","volume":"6","author":"Ross","year":"2019","journal-title":"Mov Disord Clin Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajmg.b.31232","article-title":"Indexing disease progression at study entry with individuals at-risk for Huntington disease","author":"Zhang","year":"2011","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"B11","unstructured":"Double Setback for ASO Trials in Huntington Disease2021"},{"key":"B12","doi-asserted-by":"publisher","first-page":"RRN1184","DOI":"10.1371\/currents.RRN1184","article-title":"Observing Huntington's disease: the European Huntington's disease network's REGISTRY","volume":"2","author":"Orth","year":"2010","journal-title":"PLoS Curr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","article-title":"Detection of Huntington's disease decades before diagnosis: the Predict-HD study","volume":"79","author":"Paulsen","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e29522","DOI":"10.1371\/journal.pone.0029522","article-title":"Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study","volume":"7","author":"Dorsey","year":"2012","journal-title":"PLoS One."},{"key":"B15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ebiom.2015.08.002","article-title":"Compensation in preclinical Huntington's disease: evidence from the track-On HD study","volume":"2","author":"Kl\u00f6ppel","year":"2015","journal-title":"EBioMedicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Huntington Study Group","volume":"11","year":"1996","journal-title":"Mov Disord"},{"key":"B18","doi-asserted-by":"publisher","first-page":"eabc2888","DOI":"10.1126\/scitranslmed.abc2888","article-title":"Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease","volume":"12","author":"Rodrigues","year":"2020","journal-title":"Sci Transl Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/mds.25964","article-title":"HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3","volume":"29","author":"Stout","year":"2014","journal-title":"Mov Disord"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/ptj\/pzz075","article-title":"Physical Activity and Exercise Outcomes in Huntington Disease (PACE-HD): protocol for a 12-month trial within cohort evaluation of a physical activity intervention in people with huntington disease","volume":"99","author":"Drew","year":"2019","journal-title":"Phys Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","article-title":"Identification of genetic factors that modify clinical onset of Huntington's disease","volume":"162","year":"2015","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","article-title":"CAG repeat not polyglutamine length determines timing of Huntington's disease onset","volume":"178","year":"2019","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/arclin\/acaa026","article-title":"Cognitive and motor norms for Huntington's disease","volume":"35","author":"Mills","year":"2020","journal-title":"Arch Clin Neuropsychol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1007\/s00415-012-6415-8","article-title":"Substance abuse may be a risk factor for earlier onset of Huntington disease","volume":"259","author":"Byars","year":"2012","journal-title":"J Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1212\/WNL.0000000000003661","article-title":"Substance abuse may hasten motor onset of Huntington disease: evaluating the Enroll-HD database","volume":"88","author":"Schultz","year":"2017","journal-title":"Neurology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.parkreldis.2021.01.010","article-title":"Estimating the causal effects of modifiable, non-genetic factors on Huntington disease progression using propensity score weighting","volume":"83","author":"Griffin","year":"2021","journal-title":"Parkinsonism Relat Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/jamiaopen\/ooy060","article-title":"A probabilistic disease progression modeling approach and its application to integrated Huntington's disease observational data","volume":"2","author":"Sun","year":"2019","journal-title":"JAMIA Open."},{"key":"B29","first-page":"1","article-title":"Registries for evaluating patient registries: a user's guide","volume-title":"Agency for Healthcare Research and Quality, publication No. 07-EHC001","author":"Gliklich","year":"2007"},{"key":"B30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13023-019-1139-9","article-title":"RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework","volume":"14","author":"Bellgard","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cts.12500","article-title":"Future of rare diseases research 2017-2027: an IRDiRC perspective","volume":"11","author":"Austin","year":"2018","journal-title":"Clin Transl Sci."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.667420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T06:04:28Z","timestamp":1629266668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.667420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":31,"alternative-id":["10.3389\/fneur.2021.667420"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.667420","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"article-number":"667420"}}